| Budget Amount *help |
¥110,240,000 (Direct Cost: ¥84,800,000、Indirect Cost: ¥25,440,000)
Fiscal Year 2014: ¥19,370,000 (Direct Cost: ¥14,900,000、Indirect Cost: ¥4,470,000)
Fiscal Year 2013: ¥20,280,000 (Direct Cost: ¥15,600,000、Indirect Cost: ¥4,680,000)
Fiscal Year 2012: ¥21,320,000 (Direct Cost: ¥16,400,000、Indirect Cost: ¥4,920,000)
Fiscal Year 2011: ¥21,060,000 (Direct Cost: ¥16,200,000、Indirect Cost: ¥4,860,000)
Fiscal Year 2010: ¥28,210,000 (Direct Cost: ¥21,700,000、Indirect Cost: ¥6,510,000)
|
|---|
| Outline of Final Research Achievements |
Development of the project-wide software platform is the mission of the group. Based on cellular level modeling that is relatively well established, we have expanded our platform to be able to create multi-scale physiological model for drug effect predictions. PhysioDesigner modeling software, PHML description language, and Flint simulation core have been developed and widely distributed. In parallel, we have delved into molecular interactions for broad-coverage high precision docking simulation using machine learning and parallel execution of multiple docking strategies. Furthermore, Garuda alliance was formed and the official version of Garuda Platform was released, and now widely used by pharmaceutical companies. Combined together, we have accomplished our initial commitment of platform development, and we consider it is very successful.
|
